血小板无力症的诊治新进展*

doi:10.3969/j.issn.1671-2587.2022.02.022

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (2): 244-248.DOI: 10.3969/j.issn.1671-2587.2022.02.022

血小板无力症的诊治新进展^*

黎海燕, 李保才, 李丽君

530100 广西医科大学附属武鸣医院输血科

收稿日期:2021-09-02 发布日期:2022-04-12
通讯作者: 李保才,男,主任技师,主要从事输血医学方面研究,（E-mail）15177298885@163.com。
作者简介:黎海燕（1978-）,女,广西博白人,副主任医师,博士,主要从事输血医学方面研究,（E-mail）lhy512moon@aliyun.com。
基金资助:
*本课题受广西壮族自治区卫生健康委员会西医自筹经费科研课题（NO. 20210415）资助

Received:2021-09-02 Published:2022-04-12

摘要/Abstract

摘要： 血小板无力症（Glanzmann thrombasthenia,GT）是由于血小板膜表面整合素αⅡbβ3障碍导致的先天性出血性疾病,由于该病的罕见性,很少临床医生对GT有丰富的经验,治疗仍面临着许多挑战。本文就这几年来GT的临床表现、实验室检查、分子基础和治疗措施的新进展做一综述,期望能帮助临床医生进一步提高对该病的诊断和治疗水平。

关键词: 血小板无力症, αⅡbβ3, GPⅡb/Ⅲa, 血小板糖蛋白

中图分类号:

黎海燕, 李保才, 李丽君. 血小板无力症的诊治新进展^*[J]. 临床输血与检验, 2022, 24(2): 244-248.

[1] QIAO Z G,CHEN Y,SHI W,et al.Glanzmann's thrombasthenia with spontaneous upper gastrointestinal bleeding:a case report[J].J Int Med Res,2020,48(3):300060520904849.
[2] ALIOTTA A,KRÜSI M,BERTAGGIA CALDERARA D,et al.Characterization of procoagulant COAT platelets in patients with glanzmann thrombasthenia[J]. Int J Mol Sci,2020,21(24):9515.
[3] BOTERO J P,LEE K,BRANCHFORD B R,et al.Glanzmann thrombasthenia:genetic basis and clinical correlates[J]. Haematologica,2020,105(4):888-894.
[4] PK R,SANKARAN B P.Tay-Sachs disease.2020 nov 17.in:StatPearls[Internet].treasure island (FL):StatPearls publishing;2021.
[5] 周鹭,陈秀芳,江淼,等. 血小板无力症97例临床发病特征分析[J]. 交通医学,2019,33(2):162-164.
[6] HUANG J S,LI X,SHI X F,et al.Platelet integrin αⅡbβ3:signal transduction,regulation,and its therapeutic targeting[J].J Hematol Oncol,2019,12(1):26.
[7] MATHEWS N,RIVARD G E,BONNEFOY A.Glanzmann thrombasthenia:perspectives from clinical practice on accurate diagnosis and optimal treatment strategies[J]. J Blood Med,2021,12:449-463.
[8] CHAUDHARY P K,KIM S,JEE Y,et al.Characterizati on of integrin αⅡbβ3-mediated outside-in signaling by protein kinase cδ in platelets[J].Int J Mol Sci,2020,21(18):6563.
[9] SUN Z Q,COSTELL M,FÄSSLER R.Integrin activation by talin,kindlin and mechanical forces[J].Nat Cell Biol,2019,21(1):25-31.
[10] 班建东,齐凤娜,冯向辉,等. 遗传性血小板无力症洁治后牙龈出血1例[J]. 实用口腔医学杂志,2020,36(4):690-691.
[11] 孙安霞. 2例遗传性血小板无力症临床表型和基因型分析并文献复习[D].遵义医科大学,2019.
[12] 曹满雄,江迦典,洪佳琼,等.一个新的导致血小板无力症的ITGA2B基因无义突变[J].汕头大学医学院学报,2020,33(3):147-151.
[13] 甘芳宴,屈晨雪. 血小板无力症发病机制研究进展[J]. 临床检验杂志,2019,37(9):686-690.
[14] GRAINGER J D,THACHIL J,WILL A M.How we treat the platelet glycoprotein defects;Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults[J].Br J Haematol,2018,182(5):621-632.
[15] OWAIDAH T,SALEH M,BAZ B,et al.Molecular yield of targeted sequencing for Glanzmann thrombasthenia patients[J]. NPJ Genom Med,2019,4:4.
[16] MUTREJA D,SHARMA R K,PUROHIT A,et al.Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia:association with bleeding symptoms[J]. Indian J Med Res,2017,145(5):629-634.
[17] NURDEN A T,PILLOIS X,NURDEN P.Understanding the genetic basis of Glanzmann thrombasthenia:implications for treatment[J]. Expert Rev Hematol,2012,5(5):487-503.
[18] MUNNIX I C A,VAN OERLE R,VERHEZEN P,et al. Harmonizing light transmission aggregometry in the Netherlands by implementation of the SSC-ISTH guideline[J]. Platelets,2021,32(4):516-523.
[19] YUE C,LIN Z W,LU C X,et al.Efficacy of monitoring platelet function by an automated PL-12 analyzer during the treatment of acute cerebral infarction with antiplatelet medicine[J]. Clin Appl Thromb Hemost,2021,27:10760296211001119.
[20] VALSAMI S,KOLLIA M,MOUGIOU V,et al.Evaluation of PFA-100 closure times in cord blood samples of healthy term and preterm neonates[J]. Clin Chem Lab Med,2020,58(4):e113-e116.
[21] AHAMMAD J,KAMATH A,SHASTRY S,et al.Clinico-hematological and thromboelastographic profiles in glanzmann's thrombasthenia[J]. Blood Coagul Fibrinolysis,2020,31(1):29-34.
[22] COMPTON F,SARODE R,RUTHERFORD C,et al.Acquired Glanzmann's thrombasthenia:diagnosis aided by platelet aggregation mixing study[J]. Haemophilia,2020,26(2):e41-e43.
[23] NURDEN A T.Acquired Glanzmann thrombasthenia:from antibodies to anti-platelet drugs[J]. Blood Rev,2019,36:10-22.
[24] CANAULT M,ALESSI M C.RASGRP2 structure,function and genetic variants in platelet pathophysiology[J]. Int J Mol Sci,2020,21(3):1075.
[25] ROSENBERG N,DARDIK R,HAUSCHNER H,et al.Mutations in RASGRP2 gene identified in patients misdiagnosed as Glanzmann thrombasthenia patients[J]. Blood Cells Mol Dis,2021,89:102560.
[26] POON M C,DI MINNO G,D'OIRON R,et al. New insights into the treatment of glanzmann thrombasthenia[J]. Transfus Med Rev,2016,30(2):92-99.
[27] DI MINNO G,ZOTZ R B,D'OIRON R,et al. The international,prospective Glanzmann Thrombasthenia Registry:treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia[J]. Haematologica,2015,100(8):1031-1037.
[28] POON M C.The use of recombinant activated factor VⅡ in patients with glanzmann's thrombasthenia[J]. Thromb Haemost,2021,121(3):332-340.
[29] ANDIÇ N,O\U011FUZ N,GÜNDÜZ E,et al. Weekly low-dose recombinant factor VⅡa prophylaxis in Glanzmann thrombasthenia[J]. Blood Coagul Fibrinolysis,2021,32(5):349-351.
[30] SONI P,MANTRI S,PRABHUDESAI A,et al.Triple jeopardy:a case of Glanzmann's thrombasthenia with anti-GPⅡb-Ⅲa antibodies and HPA incompatibility resulting in stillbirth[J]. Thromb Res,2019,181:141-144.
[31] WILCOX D A,OLSEN J C,ISHIZAWA L,et al.Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia[J]. Blood,2000,95(12):3645-3651.
[32] FANG J,HODIVALA-DILKE K,JOHNSON B D,et al.Therapeutic expression of the platelet-specific integrin,alphaⅡbbeta3,in a murine model for Glanzmann thrombasthenia[J]. Blood,2005,106(8):2671-2679.

血小板无力症的诊治新进展^*

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们